Linifanib，又称利尼伐尼，是可口服的VEGFR和PDGFR家族多靶点抑制剂，作用于Flt-1/3、KDR、CSF-1R和PDGFRβ的IC₅₀分别为3 nM、4 nM、4 nM、3 nM和66 nM，具有潜在抗癌活性。

参考文献

[1] Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006. doi: 10.1158/1535-7163(IF:4.856).

[2] Hernandez-Davies JE, Zape JP, Landaw EM, et al. The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway. Mol Cancer Ther. 2011 Jun;10(6):949-59. doi: 10.1158/1535-7163.MCT-10-0904(IF:4.856).

[3] Banchi M, Orlandi P, Gentile D, et al. Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer. Am J Cancer Res. 2020 Jul 1;10(7):2120-2127(IF:4.737).

-25~-15℃保存，有效期3年。